( EVANSTON Ill.--(BUSINESS WIRE)--May 23...)Northfield Laboratories Reports Results of Pivotal Phase III Trauma,Study,Health

EVANSTON, Ill.--(BUSINESS WIRE)--May 23, 2007 - Northfield Laboratories, Inc. (NASDAQ: NFLD) reported today results of its pivotal Phase III trauma trial with PolyHeme(R), its human hemoglobin-based oxygen-carrying red blood cell substitute. The trial was designed to seek an indication for use in the treatment of life-threatening red blood cell loss when transfusion is required and red blood cells are not available, not for use interchangeably with blood. This indication addresses a critical, unmet medical need.

The primary efficacy endpoint of the study was a dual superiority-noninferiority assessment of mortality at 30 days after injury. The margin to assess noninferiority, using the upper limit of the confidence interval, was set at 7% more than control. In the primary Modified Intent to Treat population, the upper limit was 7.65%. In the As Treated population, the upper limit was 7.06%. In the Per Protocol population, the upper limit was 6.29%.

Day 30 mortality was also a primary safety endpoint. Further analysis of the mortality data indicates that the difference in mortality at 30 days between patients who received PolyHeme beginning at the scene and continuing for up to 12 hours following injury, and control patients who received the standard of care, including early blood, was not statistically significant.

"The results of this study are best understood in the context of bleeding patients who do not have early access to blood transfusion," said Steven A. Gould, M.D., Chairman and Chief Executive Officer. "47 million Americans live more than an hour away from a trauma center where blood is available. Mortality rates in that scenario would be considerably higher than those observed in the control patients in the urban setting of this trial, where transit times were relatively short. We believe that when our data are extrapolated to patients who need an oxygen carrier and have delayed access
'"/>

Page: 1 2 3 4 5 6 7 8
Related medicine technology :

1. Northfield Laboratories Investor Update
2. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
3. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study for Milnacipran as a Treatment for Fibromyalgia Syndrome
4. Columbia Laboratories Reports Preliminary Findings from the Ongoing Data Analysis of the Phase III Clinical Study of PROCHIEVE 8% (progesterone gel) to Prevent Preterm Birth
5. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
6. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
7. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
8. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
9. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
10. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
11. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection